Becton, Dickinson and Company
$17.8M 12,620 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. reported $17,843,472.30 across General Payments, Research, and Ownership to 2,488 physicians and teaching hospitals across 6,193 transactions.
- $17.8M Top 10% payer
- All-tracks total
- 6,193 Top quartile volume
- Transactions
- 2,488 Top quartile reach
- Recipients
- +$153.1K
- General Payments vs PY2023
Ultragenyx Pharmaceutical Inc. reported $17,843,472.30 across all CMS Open Payments tracks (General + Research + Ownership) to 2,488 physicians and teaching hospitals in Program Year 2024 - ranking #102 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $454,574.21, averaging $7.2K per recipient.
How Ultragenyx Pharmaceutical Inc.'s $17.8M all-tracks total breaks down
Ultragenyx Pharmaceutical Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
69/100
Total payments
A
100/100
Transaction volume
D
55/100
Physician reach
F
29/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ultragenyx-pharmaceutical-inc Ultragenyx Pharmaceutical Inc.
$17.8M · #102/1,925 · 0.1% industry · PY2024
- TOT $17.8M
- RANK #102
- SHARE 0.1%
- TXN 6,193
- RCP 2,488
- CAT 7
- GEN $454.6K
- ΔGEN +$153.1K
- TOP1 18.6%
- PY 2024
Volume peers
Nearest volume peer: Becton, Dickinson and Company ($17.8M)
Ultragenyx Pharmaceutical Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ultragenyx Pharmaceutical Inc.'s CMS-reported General Payments increased by $153.1K (+50.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ULTRAGENYX PHARMACEUTICAL INC.PY2023: ULTRAGENYX PHARMACEUTICAL INC.PY2024: Ultragenyx Pharmaceutical Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $301,506.20
- PY2024
- $454,574.21
What the Data Shows for Ultragenyx Pharmaceutical Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Ultragenyx Pharmaceutical Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 7-category general-payment breakdown below at $207.1K (45.6% of General Payments, 58 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Ultragenyx Pharmaceutical Inc.'s 7-category general-payment breakdown at $207.1K, 45.6% of the reported total.
Ultragenyx Pharmaceutical Inc. reports 7 general-payment categories - the top three are Consulting Fee (45.6%), Compensation for Services Other Than Consulting (23.6%), and Food and Beverage (13.8%). The remaining 4 categories make up 17.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Ultragenyx Pharmaceutical Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $207.1K | 58 | 45.6% |
| Compensation for Services Other Than Consulting | $107.3K | 26 | 23.6% |
| Food and Beverage | $62.6K | 2,328 | 13.8% |
| Travel and Lodging | $38.7K | 59 | 8.5% |
| Grant | $27.0K | 2 | 5.9% |
| Space Rental or Facility Fees | $11.5K | 4 | 2.5% |
| Education | $330.00 | 11 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $197,341.04 (43.4%) of $454,574.21 in this company's General Payments records across 2,061 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ultragenyx Pharmaceutical Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Nicholas Ah Mew
$84,560.00 across 9 reported transactions
- 2
Gerald Cox
$31,850.00 across 7 reported transactions
- 3
Laura Konczal
$30,839.42 across 33 reported transactions
- 4
Joseph Wolfsdorf
$25,091.62 across 11 reported transactions
- 5
Childrens Hospital Corporation
$25,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ultragenyx Pharmaceutical Inc. ranks #102 of 1,925 by total payments (top 5% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,214 of 1,838 by HHI (bottom 34% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Roche Molecular Systems, Inc. : $3.5M total payments, HHI 638
- Aroa Biosurgery Incorporated : $591.0K total payments, HHI 637
- Napo Pharmaceuticals Inc : $189.6K total payments, HHI 636
- Arthrosurface Incorporated : $1.8K total payments, HHI 636
- B. Braun Interventional Systems Inc. : $271.8K total payments, HHI 635
- Aesculap, Inc. : $921.5K total payments, HHI 634
- Ultragenyx Pharmaceutical Inc. (this company) : $454.6K total payments, HHI 634
- Pulmonx Corporation : $847.7K total payments, HHI 633
- SurGenTec : $704.8K total payments, HHI 632
- Zak Ortho : $11.4K total payments, HHI 631
- Bio-Rad Laboratories, Inc. : $421.2K total payments, HHI 631
- MorphoSys, US Inc. : $36.1K total payments, HHI 630
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ultragenyx Pharmaceutical Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ultragenyx Pharmaceutical Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ultragenyx Pharmaceutical Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
CSL Plasma Inc.
$17.9M 12,905 recipients
Compare payment profiles
Taiho Oncology, Inc.
$17.6M 5,970 recipients
Compare payment profiles
Spinecraft, LLC
$18.2M 27 recipients
Compare payment profiles
Sun Pharmaceutical Industries Inc.
$18.3M 77,951 recipients
Compare payment profiles
Sarepta Therapeutics, Inc.
$17.2M 1,307 recipients
Compare payment profiles
Put this to use
Ultragenyx Pharmaceutical Inc. ranks #102 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Ultragenyx Pharmaceutical Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Ultragenyx Pharmaceutical Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.